drugset / Trial / NCT04073615
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.
Timeline
- Start
- 2019-11-18
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | — | Oral |
| Subject | Trifluridine/Tipiracil | Unknown | — | Oral |